I agree DEW 100%. Roche has signed up now to protect it's existing HCV franchise and potentially remain a major player in the market by developing new innovative regimens. Now, let's recap, JNJ is in now, NVS has upped the ante with IDIX and HGSI, Roche just signed on ITMN, which BP will be next to ante up in this indication? What about SGP, PFE and GSK?
Market Data 
Markets 
AI
